# Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

> **NCT01051765** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Carcinoma

## Interventions

- **DRUG:** irinotecan/cisplatin

## Key facts

- **NCT ID:** NCT01051765
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051765, "Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01051765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*